Recursion Raises $200 Million, Reports Durable Polyp Reductions in FAP and Sanofi Milestone

Recursion announces oversubscribed $200M raise, positive Phase 1b/2 FAP data for REC-4881, early REC-1245 activity, and Sanofi option milestone.